Peptide Bioavailability: Why Route of Administration Matters

What Bioavailability Means

Bioavailability is the percentage of a drug that makes it to the systemic circulation in its active form. Intravenous injection is the reference point — 100% bioavailability by definition, since the drug goes directly into the blood. Every other route loses some fraction to degradation, poor absorption, or first-pass metabolism.

For peptides, this matters more than for small-molecule drugs. Peptides are large, hydrophilic molecules that don't cross membranes easily, and they're made of amino acids — which means every protease in your body sees them as food. The route of administration determines how much of the gauntlet a peptide has to run before reaching its target.

Subcutaneous Injection

Sub-Q injection deposits the peptide into the fat layer beneath the skin. From there, it's absorbed into capillaries and enters the bloodstream. Bioavailability is high — typically 75-100% for most peptides, depending on molecular size and the specific injection site.

The absorption is slower than intramuscular (because fat tissue has less blood supply than muscle), which creates a more gradual concentration curve. For many peptides, this is actually desirable — a sustained absorption profile rather than a sharp spike.

Downsides: requires injection (barrier for some), absorption rate varies with body composition and injection site, and some peptides can cause localized reactions (redness, itching) at the injection point.

This is the default route for most research peptides, and for good reason: high bioavailability, simple technique, well-understood pharmacokinetics.

Intramuscular Injection

IM injection delivers the peptide directly into muscle tissue, which has a rich blood supply. Absorption is generally faster than sub-Q, and bioavailability is comparable (80-100%).

For most research peptides, IM injection offers no meaningful advantage over sub-Q and requires a longer needle and more precise technique. The main use case is for larger-volume injections or peptides that need rapid systemic absorption.

Most researchers use sub-Q over IM for convenience and comfort. The pharmacokinetic differences for typical peptide doses are minimal.

Intranasal Delivery

The nasal mucosa is thin, highly vascularized, and — critically — provides a direct route to the brain through the olfactory nerve pathway. This makes intranasal delivery uniquely interesting for neuroactive peptides like selank and semax.

Systemic bioavailability from intranasal delivery is modest: 10-30% for most peptides. But for brain-targeted peptides, the relevant bioavailability is in the CNS, not the blood. Studies with radiolabeled peptides have shown that intranasal delivery achieves brain concentrations that are proportionally much higher than what you'd predict from blood levels. The peptide is taking a shortcut.

Limitations: the nasal mucosa surface area is small, so the amount of peptide that can be absorbed per administration is limited. Concentrated solutions are preferred. Nasal congestion reduces absorption. And the technique matters — the peptide needs to reach the upper nasal cavity (olfactory region), not just the lower airways.

Oral: The Challenge

Oral delivery is the holy grail and the biggest headache of peptide pharmacology. The GI tract is specifically designed to digest proteins and peptides — stomach acid denatures them, pepsin and other proteases cleave them, and the intestinal epithelium doesn't let large hydrophilic molecules through easily.

The result: oral bioavailability for most peptides is less than 1-2%. Oral semaglutide (Rybelsus) achieves about 1% bioavailability, and that's considered a triumph of formulation engineering — it uses SNAC, a permeation enhancer that protects the peptide and promotes absorption.

BPC-157 is the notable exception. Multiple animal studies show oral BPC-157 retaining biological activity. The mechanism isn't fully understood but may relate to BPC-157's inherent acid stability (it was originally isolated from gastric juice) and its ability to act locally on the GI mucosa before needing systemic absorption.

For most other peptides, oral delivery requires either protective formulation technology or acceptance that you're wasting 99% of the dose.

Topical Delivery

The skin is a barrier, and it's very good at its job. Most peptides can't cross the stratum corneum without help. Topical delivery is mainly relevant for skincare peptides (GHK-Cu, SNAP-8) and localized applications.

Penetration enhancers, lipophilic modifications (adding fatty acid chains), liposomal formulations, and microneedling are all strategies to improve topical peptide absorption. Each has tradeoffs between penetration depth, distribution, and practicality.

For systemic effects, topical delivery is not practical for most peptides. For local effects in the skin (collagen stimulation, wrinkle reduction), it can be effective when the formulation is right.

Choosing Your Route

The decision tree is pretty straightforward:

• Systemic effects (body composition, recovery, hormones): Sub-Q injection. Highest bioavailability, proven pharmacokinetics.
• Brain/CNS effects (cognition, mood, neuroprotection): Intranasal. Direct CNS access bypassing blood-brain barrier.
• Gut effects (GI healing, mucosal protection): Oral (for BPC-157) or Sub-Q. BPC-157 is the rare peptide where oral delivery is supported by data.
• Skin effects (collagen, wrinkles): Topical with penetration enhancement, or sub-Q for deeper tissue effects.
• Local tissue effects (specific injury site): Sub-Q injection near the target area. Whether proximity matters for sub-Q peptides is debated, but many protocols specify it.